James J. Harding

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

Cholangiocarcinoma and Gallbladder Cancer Studies · Surgery

h-index54

i10-index130

Publications583

Citations17,970

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 138

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Clinical Cancer Research · 2026-06-26
Figure 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table S2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table S3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Video S5 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Figure S1 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table S4 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table S2 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table S6 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Figure S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table 4 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table S1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Supplementary Materials from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Data from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table 3 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Figure S5 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table S1 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table S5 from IL10R Inhibition Induces Neutrophil Tumoricidal Activity
2026-06-17
Table 1 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17
Table 2 from BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
2026-06-17

Open author page on OpenAlex →